BD (Becton, Dickinson and Company) has introduced HemoSphere Alta, an advanced hemodynamic monitoring platform designed to assist clinicians in managing blood pressure changes and improving patient outcomes during medical procedures. This launch marks the first major product release from BD’s Advanced Patient Monitoring division following a recent acquisition. The platform integrates artificial intelligence algorithms to offer real-time insights, including the Acumen Hypotension Prediction Index (HPI), which helps predict low blood pressure events and reduce their severity and duration. A notable addition is the Cerebral Autoregulation Index (CAI), which provides clinicians with a personalized view of a patient’s ability to maintain stable brain blood flow under shifting blood pressure conditions.
The platform uses both invasive and noninvasive sensors, ForeSight IQ and Acumen IQ, to deliver tailored data, offering clinicians a better understanding of individual patient thresholds. It also includes design updates such as a larger touchscreen, customizable display, and hands-free interaction through voice and gesture controls, helping maintain a sterile field. Experts in anesthesiology note that CAI could be an essential tool for detecting impaired blood flow regulation, potentially lowering risks linked to insufficient cerebral perfusion. This launch aligns with BD’s ongoing focus on working closely with healthcare providers to support patient safety and workflow efficiency through technology.
